Immunocore(IMCR)
OXFORDSHIRE, United KingdomBiotechnology
Focus: Immunocore is a UK-based public biotech specializing in T Cell Receptor (TCR) fragment therapies for oncology and infectious diseases. The company has achieved commercial traction with KIMMTRAK (tebentafusp) at peak lifecycle and maintains a pipeline of 19 active programs across multiple indications.
Profile data last refreshed 11h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Immunocore
AI assessmentNot HiringNo open roles listed right now. Follow Immunocore to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Immunocore's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$249M
Key Products
Peak
Lead approved product driving $249M FY2025 revenue; mechanism targets glycoprotein 100-HLA interactions in uveal melanoma, addressing high unmet need in rare indication.
Products & Portfolio (1)
Help build intelligence for Immunocore
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.